Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.
Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 ...
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN ...
Alnylam Pharma’s Promising Clinical Data Tempered by Market Factors in Hold Rating Assessment
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...
Buy Rating Affirmed for Alnylam Pharma on Strong Phase 3 Trial Results and Favorable Sales Forecast
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...
The Pharma Letter5d
New Alnylam HELIOS-B vutrisiran data presented at HFSA
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
ENDPOINTS NEWS1d
Al­ny­lam agrees to drop patent law­suit against Mod­er­na over Covid-19 vac­cine
Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...
Investing4d
Alnylam stock holds Buy rating, price target post-data detail
On Tuesday, Canaccord Genuity maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) shares with a steady price target of $366.00. The endorsement comes after Alnylam, alongside BridgeBio ...
Investing5d
Alnylam stock holds Buy rating, price target post-data detail
On Tuesday, Canaccord Genuity maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) shares with a steady price target of $366.00. The endorsement comes after Alnylam, alongside ...